Outcome of mucormycosis after treatment: report of five cases  by Bellazreg, F. et al.
ORIGINAL ARTICLEOutcome of mucormycosis after treatment: report of ﬁve casesF. Bellazreg1, Z. Hattab1, S. Meksi2, S. Mansouri1, W. Hachﬁ1, N. Kaabia1, M. Ben Said2 and A. Letaief1
1) Service de Maladies Infectieuses and 2) Laboratoire de Parasitologie – Mycologie, CHU Farhat Hached, Sousse, TunisieAbstractMucormycoses are serious infections caused by ﬁlamentous fungi of the order Mucorales. They occur most often in immunocompromised
patients. We report ﬁve cases of mucormycosis in patients hospitalized in the Infectious Diseases Department in Sousse – Tunisia
between 2000 and 2013. They were 4 males and one female, mean age 60 years. Three patients were diabetic and one patient had acute
leukemia. The locations of mucormycosis were rhinocerebral, rhino-orbital, auricular, pulmonary and cutaneous. The Mucorales isolated
were Rhizopus arrhizus in 3 cases and Lichteimia in 2 cases. All patients were treated with amphotericin B and 2 patients had, in addition,
surgical debridement. Two patients died and 2 kept peripheral facial paralysis.
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E-mail: amel.letaief@famso.rnu.tnIntroductionMucormycosis is a rare but serious infection due to ﬁla-
mentous fungi of the division of Mucorales, the class Zygo-
mycetes. They occur most often in immunocompromised
patients with diabeties or haematological malignancies with
prolonged neutropenia they represent the third cause of
fungal infection in these patients after invasive candidiasis and
aspergillosis [1,2]. We report ﬁve cases of conﬁrmed
mucormycosis in patients hospitalized in the Infectious Dis-
eases department of Sousse, Tunisia, between 2000 and
2013.ResultThe main data are summarized in Table 1.© 2015 New Microbes and New Infections published by El
This is an open access artiThe patiuents were four men and one woman, mean age 60
years (25–77 years). Three patients had type 2 diabetes, one
patient had acute leukemia (AL) in treatment failure with pro-
longed neutropenia and one patient was immunocompetent.
Mucormycosis was rhino-cerebral, rhino-orbital, auricular (left
otitis media), pulmonary and cutaneous. The mean duration of
symptoms was 11 days (2–30 days).
Clinical signs included fever (all cases), peripheral facial palsy
(PFP) and an orbital edema (two cases each), subcutaneous
frontal abscess (Fig. 1) with mental confusion, ear pain with
purulent otorrhea and hearing loss left, productive cough with
dyspnea and necrotizing fasciitis of the left leg. Ketotic
decompensation was noted in three patients with diabetes. All
patients had received antibiotics before diagnosis of mucor-
mycosis. The diagnosis of mucormycosis was made after
average 17 days of hospitalization (2–57 days).Imaging and laboratory dataComputed tomography (CT) of the facial bones showed pan-
sinusitis in two patients, associated with subcutaneous frontal
abscess in a patient.
CT showed a rocks ﬁlling the mastoid cells in a patient.New Microbe and New Infect 2015; 6: 49–52
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TABLE 1. Main clinical, therapeutic and outcome data in 5 patients with mucormycosis
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Year of diagnosis 2007 2011 2012 2012 2013
Gender, age (years) F, 72 M, 77 M, 25 M, 54 M, 76
Comorbiditie (s) Type 2 diabetes None Acute leukemia Type 2 diabetes Type 2 diabetes
Infection localisation Rhino-orbital
pansinusitis
Chronic otitis media Necrotizing fasciitis Pneumonia Rhino-cerebral + pansinusitis
Clinical signs Hemiface
inﬂammation
Otalgia, otorrhea,
hypoacusis; PFP
Leg necrotizing
inﬂammation
Cough, fever, dyspnea Front subcutaneous
abscess; confusion
Disease duration (days) 2 30 15 4 4
CT scan Pansinusitis;
infraorbital
abscess
Filling the mastoid cells — Bilateral alveolo-interstitial
syndrome
Pansinusitis
Direct examination
Culture
Hyphae
Lichtemia
Hyphae
Lichtemia
Negative
Lichtemia
Hyphae
Rhizopus arrhizus
Negative
Rhizopus arrhizus
Diagnostic delay (days) 57 15 7 2 7
Ampho B duration (days)
Ampho B side effects
Surgery
46
ARF
Yes
34
Hypokalemia; ARF
No
21
None
Yes
15
None
No
4
None
No
Outcome Sequelae/PFP Sequelae/PFP Local improvement
death/shok-multiorgan failure
Death/ARDS Death/brain hemorrhage
F: female, M: male; PFP: peripheral facial paralysis; ampho B: amphotericin B;
ARF: acute renal failure; ARDS: Acute respiratory distress syndrome.
50 New Microbes and New Infections, Volume 6 Number C, July 2015 NMNIChest CT showed bilateral alveolar-interstitial inﬁltrate with
alveolar consolidation in the right lower lobe (Fig. 2). The
magnetic resonance imaging (MRI) showed bilateral predomi-
nantly frontal right lesion hyperintense on T2-Flair in a patient
(Fig. 3).
The direct examination showed live mycological wide non
septate hyphae with irregular diameter, indicative of Mucorales,
in three cases. Culture was positive in all cases. Mucorales were
isolated from the following samples: pus from the subcutaneous
frontal abscess obtained by needle puncture, pus ear swab
obtained on ﬁve different samples spaced several days, sinus
biopsy, bronchial biopsy and intraoperative biopsy the soft
tissue. It was identiﬁed as Lichteimia corymbifera (formerly
Absidia corymbifera) in three cases and Rhizopus arrhizus in two
cases.FIG. 1. Frontal abscess with right orbital subcutaneous edema in one
patient with mucormycosis.
© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Soc
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceTreatment – EvolutionAll patients were treated with intravenous amphotericin B 0.7
to 1 mg / kg / day. Apart from one patient who died after four
days of hospitalization, the mean duration of treatment was 32
days (15–46). Hypokalemia was observed in one patient in the
course of moderate acute renal failure at the end of treatment
in two patients. In two cases, the treatment was continued with
correction of hypokalemia and hydration.
The evolution was marked by the early death in two patients
(inter- hemispheric cerebral hematoma complicated with coma
and respiratory distress in one case, and extensive pneumonia
with respiratory distress in one case) and persistent sequelae in
two other patients (PFP in two cases and hearing loss in oneFIG. 2. Chest CT. Bilateral iterstitiel and alveolar interstitial with lower
right lobar alveolar consolidation.
iety of Clinical Microbiology and Infectious Diseases, NMNI, 6, 49–52
nses/by-nc-nd/3.0/)
FIG. 3. MRI Mucorales brain abscess: bilateral, predominantly frontal
right lesion on T2-Flair.
NMNI Bellazreg et al. Outcome of mucormycosis 51case). In one patient who had AL, treatment with amphotericin
B and surgical debridement resulted in a local improvement, but
the patient died one month after his discharge due to his un-
derlying disease.DiscussionIn our study, mucormycosis was observed more often in
immunocompromised patients (four out of ﬁve cases) and the
most common sites were rhino-cerebral and rhino-orbital.
These data are consistent with the literature data. Indeed, in
90% of cases, mucormycosis occur in immunocompromised
patients, mainly diabetic ketosis or hematological malignancy
with neutropenia. The naso-orbito-cerebral, lung and skin are
the most common [1,2].
The observed auricular localization in one of our patients,
immunocompetent is exceptional [3]. A Tunisian retrospective
study compilING 17 cases of mucormycosis between 1992 and
2007, diabetes and rhino-orbitofrontal cerebral localization was
noted in all patients [4].
In rhino-sinus mucormycosis, CT is the investigation of
choice to study the invasion of bone and soft tissue abscesses,
or hematoma, and extension to the central nervous system.© 2015 New Microbes and New Infections published by Elsevier Ltd on beha
This is an open access artiMRI is more sensitive than CT for the investigation of possible
cerebrovascular thrombosis. In pulmonary mucormycosis,
chest radiograph or better chest CT typically show alveolar
condensations sometimes excavated or nodular inﬁltrates
frosted glass with or without halo sign [5]. These nose and brain
damage and lung characteristics were observed in our patients.
Since imaging lesions are not speciﬁc of mucormycosis, a
mycological diagnosis is necessary. The reference method is the
direct examination and culturing of the pathological product:
puncture ﬂuid (pus, serous ﬂuid), tissue biopsy. Mucorales hy-
phae are short, little or no septate, thick-walled and often
branched at right angles.
The identiﬁcation of the genus and species is of epidemio-
logical interest but does not guide antifungal therapy. It is based
on macroscopic and microscopic cultural characters. These
characters are not speciﬁc where the recent use in specialized
laboratories in molecular biology techniques such as PCR
improved the etiological diagnostic [6]. The most common
mucormycosis genera are Rhizopus (47%) and Mucor (18%).
Lichteimia is responsible for 5% of the cases [2]. In a previous
Tunisian study, Rhizopus had been isolated in 70% of patients
[4]. Here, Lichteimia was isolated in three of ﬁve patients. In the
literature, this type is more frequently isolated from male pa-
tients. There is no particular geographic distribution [2].
In addition to the mycological diagnosis, histological study of
biopsy fragments are useful for the diagnosis of mucormycosis
and allows the conﬁrmation in case of Mucorales ﬁlament
presence in tissues and vessels where they are responsible for
thrombosis with infarction and hemorrhage [7].
In our study, the Mucorales were isolated from pus obtained
by percutaneous puncture or multiple swab samples in two
cases, and on biopsy fragments in three cases. Culture was
positive in all cases. The two isolated genera were Rhizopus and
Lichteimia. The predominance of the latter would be explained
by the male in our study.
The treatment of mucormycosis is mainly based on antifungal
and surgical debridement. The rapid equilibration of ketoaci-
dosis in diabetics, transfusion of hematopoietic growth factors
in long-term neutropenia and hyperbaric oxygen therapy may
be useful [8]. Reference antifungal therapy is liposomal
amphotericin B, 5 to 10 mg / kg / day. Amphotericin B deox-
ycholate should no longer be used because of its nephrotoxicity
[8]. Other antifungal posaconazole or caspofungin can be used
in combination with liposomal amphotericin B in case of
treatment failure or as a substitute for serious side effects [8].
Fluconazole, voriconazole and itraconazole have no activity on
Mucorales [9].
Mucormycosis has poor prognosis with a mortality rate of
17–51% [10]. Mortality is higher in case of diagnostic delay of
more than ﬁve days and monocytopenia in patients with activelf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 49–52
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/)
52 New Microbes and New Infections, Volume 6 Number C, July 2015 NMNImalignant blood diseases. Surgical treatment associated with
antifungals improves prognosis [2,10]. The genus or species of
Mucorales offending does not appear to inﬂuence the outcome
[10,11]. In a previous Tunisian study, mortality was 65% [4].
In our study, all patients were treated with amphotericin B
deoxycholate as liposomal amphotericin B is not available in our
country and two patients had surgical excision. Moderate renal
impairment occurred in two patients. A late diagnosis> ﬁve
days was noted in four patients. Two patients died and two kept
sequelae.ConclusionThe diagnosis of mucormycosis should be suspected in any
diabetic patient with neutropenia or neutropenic presenting
with rhino-orbitofrontal brain or lung unimproved by appro-
priate antibiotic therapy. Other locations are less characteristic.
Diagnosis is suspected on clinical and radiological features and
conﬁrmed by mycological and pathological examination.
Treatment consists of amphotericin B combined with surgery.
Morbidity and mortality are high due to the invasive nature of
the frequent underlying malignancy, hence the importance of
early and appropriate management.Conﬂict of interestNone.© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Soc
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